|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.97 CNY | +2.42% |
|
+6.39% | -10.82% |
| 07-10 | China Includes Two Mayinglong Pharmaceutical Products in Essential Medicines List | MT |
| 05-25 | Mayinglong Pharmaceutical Gets Regulatory Approval for Eye Drops | MT |
Company Valuation: Mayinglong Pharmaceutical Group Co., LTD.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10,423 | 11,255 | 12,070 | 10,763 | - | - |
| Change | - | 7.98% | 7.24% | -10.82% | - | - |
| Enterprise Value (EV) | 10,423 | 11,255 | 12,070 | 10,763 | 10,763 | 10,763 |
| Change | - | 7.98% | 7.24% | -10.82% | 0% | 0% |
| P/E | - | 21.2x | 20.7x | 16x | 13.3x | 12.7x |
| PBR | - | 2.77x | 2.76x | 2.26x | 1.96x | 1.7x |
| PEG | - | - | 2.12x | 1x | 0.6x | 2.98x |
| Capitalization / Revenue | 3.32x | 3.02x | 3.12x | 2.49x | 2.26x | 2.09x |
| EV / Revenue | 0x | 0x | 0x | 2.49x | 2.26x | 2.09x |
| EV / EBITDA | - | 0x | 0x | 13.2x | 11.8x | 10.7x |
| EV / EBIT | - | 0x | 0x | 13x | 11.6x | 10.4x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | 1.23 | 1.35 | 1.56 | 1.88 | 1.96 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,137 | 3,728 | 3,867 | 4,318 | 4,754 | 5,142 |
| EBITDA 1 | - | 686.7 | 791.2 | 817 | 911 | 1,010 |
| EBIT 1 | - | 666.8 | 719.9 | 830 | 924 | 1,039 |
| Net income 1 | 443.3 | 528.1 | 581.5 | 674 | 745 | 843 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 24.18 | 26.11 | 28.00 | 24.97 | 24.97 | 24.97 |
| Nbr of stocks (in thousands) | 431,054 | 431,054 | 431,054 | 431,054 | - | - |
| Announcement Date | 12/04/24 | 02/04/25 | 24/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.01x | - | - | - | 1.59B | |
| 34.3x | 12.25x | 25.74x | 0.59% | 1,030B | |
| 27.42x | 6.27x | 17.37x | 2.1% | 617B | |
| 32.4x | 7.6x | 15.6x | 2.67% | 455B | |
| 19.58x | 4.68x | 11.59x | 2.83% | 350B | |
| 22.31x | 5.76x | 14.38x | 2.78% | 299B | |
| 21.88x | 4.51x | 12.77x | 1.94% | 265B | |
| 14.62x | 5.41x | 11.16x | 3.43% | 225B | |
| 25.46x | 6.65x | 11.72x | 2.6% | 209B | |
| -47.31x | 5.67x | 31.32x | 2.51% | 163B | |
| Average | 16.67x | 6.53x | 16.85x | 2.38% | 361.43B | |
| Weighted average by Cap. | 24.13x | 7.76x | 18.30x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600993 Stock
- Valuation Mayinglong Pharmaceutical Group Co., LTD.
Select your edition
All financial news and data tailored to specific country editions
